ASP Isotopes (ASPI) Projected to Post Quarterly Earnings on Wednesday

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.30 million for the quarter.

ASP Isotopes Stock Performance

Shares of ASP Isotopes stock opened at $6.56 on Wednesday. The company has a market capitalization of $492.41 million, a PE ratio of -10.75 and a beta of 3.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The company has a 50-day simple moving average of $5.00 and a two-hundred day simple moving average of $5.42. ASP Isotopes has a one year low of $1.86 and a one year high of $9.33.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, COO Robert Ainscow sold 66,668 shares of the firm's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total value of $374,674.16. Following the completion of the transaction, the chief operating officer now owns 1,419,992 shares of the company's stock, valued at approximately $7,980,355.04. This trade represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Paul Elliot Mann sold 316,667 shares of the firm's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $1,820,835.25. Following the completion of the transaction, the chief executive officer now directly owns 7,948,787 shares of the company's stock, valued at approximately $45,705,525.25. This represents a 3.83% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 766,667 shares of company stock worth $4,358,502. Insiders own 21.40% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.